1. Home
  2. ARTL vs VRAX Comparison

ARTL vs VRAX Comparison

Compare ARTL & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.84

Market Cap

3.4M

Sector

Health Care

ML Signal

HOLD

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$0.66

Market Cap

2.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARTL
VRAX
Founded
2011
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
2.8M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
ARTL
VRAX
Price
$1.84
$0.66
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$30.00
$3.00
AVG Volume (30 Days)
1.3M
14.7M
Earning Date
11-12-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,986.00
Revenue This Year
N/A
$217,274.83
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.52
$0.35
52 Week High
$28.60
$3.20

Technical Indicators

Market Signals
Indicator
ARTL
VRAX
Relative Strength Index (RSI) 33.96 69.02
Support Level $1.62 $0.39
Resistance Level $1.98 $0.43
Average True Range (ATR) 0.19 0.06
MACD 0.11 0.02
Stochastic Oscillator 69.53 55.35

Price Performance

Historical Comparison
ARTL
VRAX

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

Share on Social Networks: